Cardiovascular

Risk of atrial fibrillation in patients with differentiated thyroid cancer: a nationwide population-based analysis.

TL;DR

Patients with differentiated thyroid cancer had a two-fold higher risk of incident atrial fibrillation than controls, with the risk being higher in those who underwent total thyroidectomy than those who underwent lobectomy alone.

Key Findings

Patients with differentiated thyroid cancer had a significantly higher risk of incident atrial fibrillation compared to matched controls.

  • HR of 2.07 (95% CI, 1.98–2.17) for AF in DTC patients versus controls
  • Study included 113,791 patients with DTC and 455,188 age- and sex-matched controls
  • Data drawn from the Korean National Health Information Database between 2006 and 2019
  • A Cox proportional hazards model was used to compute hazard ratios and 95% confidence intervals

All treatment modality groups (lobectomy, total thyroidectomy with or without RAIT) showed a higher risk of AF than the control group.

  • Lobectomy group: HR 1.93 (95% CI, 1.72–2.15)
  • Total thyroidectomy without RAIT: HR 2.20 (95% CI, 2.06–2.34)
  • Total thyroidectomy with RAIT: HR 2.07 (95% CI, 1.95–2.20)
  • Each treatment group was compared against matched controls, not against each other

Patients with DTC who underwent total thyroidectomy had a higher risk of AF than those who underwent lobectomy alone.

  • Total thyroidectomy without RAIT had an HR of 2.20 (95% CI, 2.06–2.34) versus lobectomy HR of 1.93 (95% CI, 1.72–2.15)
  • Total thyroidectomy with RAIT had an HR of 2.07 (95% CI, 1.95–2.20) versus lobectomy HR of 1.93 (95% CI, 1.72–2.15)
  • The study design was a retrospective cohort using nationwide population-based data
  • The authors note this finding has implications for long-term management and AF screening strategies in DTC patients

The study population was a large nationwide cohort of differentiated thyroid cancer patients identified from a Korean national database spanning over a decade.

  • 113,791 DTC patients were included with a 1:4 matching ratio yielding 455,188 controls
  • Matching was performed by age and sex
  • Data covered the period from 2006 to 2019
  • Treatment modalities assessed included lobectomy, total thyroidectomy without RAIT, and total thyroidectomy with RAIT

Thyroid hormone suppression therapy is widely used in the long-term management of differentiated thyroid cancer and has been suggested to increase AF risk.

  • THST is described as 'widely used for long-term management of differentiated thyroid cancer'
  • Prior studies have suggested THST may increase the risk of AF in DTC patients
  • The study aimed to evaluate whether AF risk differs according to treatment modality
  • Increased vigilance for AF screening is recommended, 'particularly in this high-risk group'

Have a question about this study?

Citation

Heo J, Sohn S, Kim Y, Cho S. (2026). Risk of atrial fibrillation in patients with differentiated thyroid cancer: a nationwide population-based analysis.. The Korean journal of internal medicine. https://doi.org/10.3904/kjim.2025.129